Well under way, the collaboration between these two organizations promises to offer yet another exciting project to the observers of immuno-oncology drug development, who were treated to multiple great results at ASCO 2014.
In late September, Boehringer Ingelheim announced that it has taken a licence to Curevac’s messenger RNA (mRNA) vaccine (CV9202), and will start investigations in at least two different lung cancer settings in combination with afatinib.
Patient selection will be based on metastatic epidermal growth factor (EGFR) mutated Non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC.
CureVac will receive EUR 35 million upon signature, and can achieve milestone payments of up to EUR 430 million, as well as royalties on sales.
CureVac Chief Scientific Officer Karl-Josef Kallen will present at the Skygenix World NSCLC Summit on January 27-28 in Boston, 2015.
Read more on the Boehringer Ingelheim press release..